The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | The value of using personalized approaches when treating patients with MF
Elisabetta Abruzzese, MD, PhD, St Eugenio University Hospital, Rome, Italy, briefly comments on the use of JAK2 inhibitors in myelofibrosis (MF), and further highlights the value of combining novel agents and using more personalized approaches when treating these patients. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
